个人简介
学历背景
1980.9-1985.7:湖北医科大学分院,医学学士
1985.9-1988.7:西安交通大学,医学硕士
1992.2-1996.6:瑞士日内瓦大学,医学博士
国外学习研究经历
1996.7-1998.12:宾夕法尼亚医学院药理系,博士后
1999.1-2000.12:美国宾西法尼亚州立大学医学院,博士后
工作经历
1988.9-1992.1:北京酒仙桥医院(现清华大学第一附属医院),主治医师、副主任医师
2001.1-2003.12:费城Drexel大学医学院药理系,助理教授
2004.1-2006.7:纽约城市大学医学院药理系,副教授
2006.7-2010.5:中科院上海药物研究所,研究员课题组长
2010.5至今:苏州大学药学院,特聘教授、院长
研究领域
(1)靶向神经精神重大疾病的药物研发:以精神分裂症、帕金森氏病、抑郁症、药物成瘾为靶向,寻找和发现新型小分子药物。
(2)神经递质受体调控及信号传导机制:研究神经递质特别是多巴胺受体信号及功能调控的分子机制,并探讨其在重大神经精神疾病中的作用和机理。
(3)胶质细胞及神经免疫:研究胶质细胞功能调控的机制,及其在生理病理条件下的作用,神经免疫与胶质功能调控。
近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Wang X, Chen S, Ni J, Cheng J, Jia J*, Zhen X*. miRNA-3473b contributes to neuroinflammation following cerebral ischemia.Cell Death Dis. 2018 Jan 9;9(1):11.
Cao T,Zhen X*. Dysregulation of miRNA and its potential therapeutic application in schizophrenia. CNS Neurosci Ther. 2018 Mar 12. doi: 10.1111/cns.12840.
Jia J, Cheng J, Wang C*, Zhen X*. Sigma-1 Receptor-Modulated Neuroinflammation in Neurological Diseases. Front Cell Neurosci. 2018, 12:314.
Zheng J, Zhang X*, Zhen X*. Development of Adenosine A2A Receptor Antagonists for the Treatment of Parkinson's Disease: A Recent Update and Challenge. ACS Chem Neurosci. 2018 Sep 21. doi: 10.1021/acschemneuro.8b00313.
Zhen X, Waddington J. Emerging and evolving concepts in the pathobiology and treatment of psychosis.CNS Neurosci Ther. 2018 Jul;24(7):583-585.
Yan Q, Han C, Wang G, Waddington JL, Zheng L, Zhen X*. Activation of AMPK/mTORC1-mediated autophagy by metformin reverses Clk1 deficiency - sensitized dopaminergic neuronal death. Mol Pharmacol. 2017, 92(6):640-652.
Ren Z, Yan P, Zhu L, Yang H, Zhao Y, Kirby BP, Waddington JL, Zhen X*. Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammation. Psychopharmacology (Berl). 2018 Jan;235(1):233-244.
Zhang L, Yang H, Zhang W, Liang Z, Huang Q, Xu G, Zhen X*, Zheng LT. Clk1-regulated aerobic glycolysis is involved in glioma chemoresistance. J Neurochem. 2017, 142(4):574-588.
Tian S, Wang X, Li L, Zhang X, Li Y, Zhu F, Hou T, Zhen X*. Discovery of Novel and Selective Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease through Comparative Structure-Based Virtual Screening. J Chem Inf Model. 2017, 57(6):1474-1487.
Zhao YF, Wang PP, Chen SS, Han CJ, Yan QT, Zheng LT, Jia J, Ren ZX, Zhen XC*. Dihydromyricetin protects against cerebral ischemia/reperfusion injury via suppressing microglia-mediated neuroinflammation and activation of ERK1/2-CREB signaling pathway. Journal of Functional Foods. 2017, 33: 76–84.
O'Tuathaigh CMP, Moran PM, Zhen XC, Waddington JL. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. Br J Pharmacol. 2017, 174(19):3173-3190.
Gu R., Zhang F, Chen G, Han C, Liu J, Ren Z, Zhu Y, J. L. Waddington, Zheng L, Zhen X*. Clk1 deficiency promotes neuroinflammation and subsequent dopaminergic cell death through regulation of microglial metabolic reprogramming. Brain Behav Immun. 2017, 60: 206-219.
Liu T, Yang X, Zheng L, Wang G, Zhen X*. Activation of Nur77 in microglia attenuates proinflammatory mediators production and protects dopaminergic neurons from inflammation-induced cell death. J Neurochem. 2017, 140(4): 589-604.
Wang J, Sun P, Ren Z, H. Y. Meltzer, Zhen X*. GSK-3beta Interacts with Dopamine D1 Receptor to Regulate Receptor Function: Implication for Prefrontal Cortical D1 Receptor Dysfunction in Schizophrenia. CNS Neurosci Ther. 2017, 23(2): 174-187.
Wu J, Zhao R, Guo L, Zhen X*. Morphine-induced inhibition of Ca2+ -dependent d-serine release from astrocytes suppresses excitability of GABAergic neurons in the nucleus accumbens. Addict Biol. 2017, 22(5):1289-1303
Guo L, Guo Z, Luo X, Liang R, Yang S, Ren H, Wang G, Zhen X*. Phosphodiesterase 10A inhibition attenuates sleep deprivation-induced deficits in long-term fear memory. Neurosci Lett. 2016, 635: 44-50.
Li W, Zhang L, Xu L, Yuan C, Du P, Chen J, Zhen X*, Fu W. Functional reversal of (-)-Stepholidine analogues by replacement of benzazepine substructure using the ring-expansion strategy. Chem Biol Drug Des. 2016, 88(4): 599-607.
Ren Z, Zhao Y, Cao T, Zhen X*. Dihydromyricetin protects neurons in an MPTP-induced model of Parkinson's disease by suppressing glycogen synthase kinase-3 beta activity. Acta Pharmacol Sin. 2016, 37(10): 1315-1324.
Wang Y, Guo L, Jiang H, Zheng L, Zhang A, Zhen X*. Allosteric Modulation of Sigma-1 Receptors Elicits Rapid Antidepressant Activity. CNS Neurosci Ther. 2016, 22(5): 368-377.
Yang Z, Li L, Zheng J, Ma H, Tian S, Li J, Zhang H, Zhen X*, Zhang X. Identification of a New Series of Potent Adenosine A2A Receptor Antagonists Based on 4-Amino-5-carbonitrile Pyrimidine Template for the Treatment of Parkinson's Disease. ACS Chem Neurosci. 2016, 7(11): 1575-1584.